Keywords: astrazeneca, net, income, slips, 4th, qtr, generic
AstraZeneca's net income slips 1.6% in 4th qtr as generic competition starts to bite
Article | 09 February 2009
AstraZeneca says its fourth-quarter 2008 profit fell 1.6% year-on-year to $1.25 billion, or $0.86 per share, despite a 4% rise in sales to $8.19 billion.
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- New Zealand declines Alexion's funding application for Solaris
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
